Research graph
References from Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Diabetes trends in Japan
10.1002/dmrr.296 · 2002 · External reference
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
10.1053/meta.2001.22519 · 2001 · External reference
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
10.1210/jc.2002-021545 · 2003 · External reference
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
10.1007/s001250050613 · 1996 · External reference
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis
10.1074/jbc.m209423200 · 2003 · External reference
New technologies and therapeies in the management of diabetes
2007 · External reference
Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance
10.1016/s0168-8227(02)00177-8 · 2003 · External reference
Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes
10.1507/endocrj.k08e-296 · 2009 · External reference
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
10.2337/diacare.26.8.2370 · 2003 · External reference
Unresolved reference
External reference
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
10.2337/diacare.27.11.2628 · 2004 · External reference
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
10.2337/diacare.28.5.1083 · 2005 · External reference
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
10.7326/0003-4819-146-7-200704030-00003 · 2007 · External reference
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
10.2337/diacare.28.5.1092 · 2005 · External reference
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study
10.1089/dia.2005.7.467 · 2005 · External reference
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
10.1016/j.diabres.2008.09.037 · 2009 · External reference
Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria
10.1001/archinte.161.3.397 · 2001 · External reference
Unresolved reference
External reference
Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations
10.1016/j.ecl.2004.12.002 · 2005 · External reference
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
10.1111/j.1463-1326.2006.00602.x · 2006 · External reference
Enhancing incretin action for the treatment of type 2 diabetes
10.2337/diacare.26.10.2929 · 2003 · External reference
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
10.1185/03007991003672551 · 2010 · External reference
